Patents by Inventor Michael TAGUAIM

Michael TAGUAIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETING TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER WITH A HER3-TARGETING NANOPARTICLE
    Publication number: 20180066033
    Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.
    Type: Application
    Filed: November 17, 2017
    Publication date: March 8, 2018
    Inventors: Lali K. MEDINA-KAUWE, Jessica SIMS, Michael TAGUAIM, Chris HANSON, Xiaojiang CUI
  • Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle
    Patent number: 9850293
    Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.
    Type: Grant
    Filed: April 4, 2015
    Date of Patent: December 26, 2017
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Lali K. Medina-Kauwe, Jessica Sims, Michael Taguaim, Chris Hanson, Xiaojiang Cui
  • TARGETING TRASTUZUMAB-RESISTANT HER2+ BREAST CANCER WITH A HER3-TARGETING NANOPARTICLE
    Publication number: 20160060316
    Abstract: Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy; and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell; a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions; and a chemical agent non-covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule.
    Type: Application
    Filed: April 4, 2015
    Publication date: March 3, 2016
    Inventors: Lali K. MEDINA-KAUWE, Jessica SIMS, Michael TAGUAIM, Chris HANSON, Xiaojiang CUI